about
Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury.Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles.Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications.Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?I. Arginine.Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting.Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer.On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance.Degradation of poly (isobutyl cyanoacrylate) nanoparticles.Novel microparticulate system made of poly(methylidene malonate 2.1.2).PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases.A Smart Metal-Organic Framework Nanomaterial for Lung Targeting.Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles.Nanoparticles of Metal-Organic Frameworks: On the Road to In Vivo Efficacy in BiomedicineA new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphineStacking as a Key Property for Creating Nanoparticles with Tunable Shape: The Case of Squalenoyl-DoxorubicinNanomedicines for Pediatric CancersTherapeutic Opportunities in Neuroblastoma Using NanotechnologySelective modification of a native protein in a patient tissue homogenate using palladium nanoparticlesDrug-Initiated Synthesis of Heterotelechelic Polymer Prodrug Nanoparticles for in Vivo Imaging and Cancer Cell TargetingAlbumin-driven disassembly of lipidic nanoparticles: the specific case of the squalene-adenosine nanodrugSqualene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation
P50
Q27311418-CECE3A64-C293-404C-9D63-AB970EBDA92CQ33355908-D3C818F3-08ED-4982-ABB7-18FB769CDF29Q33766617-A6612E22-2FF8-45D4-BFB0-84F84D5E9CB0Q33867421-AE878499-7676-4E29-AA73-1F20D7A82CEBQ33987176-3830DD33-8480-445F-A5EB-28CB5A1A3203Q35025743-E553E5F9-0C44-464D-AB8D-5DBC300CDC05Q40947914-6F97876F-7EEC-4BB4-81D1-315B0FF8A362Q41042772-E808A877-CF4E-4306-9CF2-23F617C507B3Q41253754-BD87892C-8CE4-48F9-AFB6-13CE02E13D35Q42256071-7100A87F-1C04-446C-9595-EF6536BCA714Q43676475-3FDF3780-45AC-4707-9A8E-CCAE6D153949Q43762536-3E827C76-E966-4872-8F73-F8B88BB17EC6Q47619632-8C1FAD4C-5A4F-47F1-8350-51054218DEE1Q54066907-91C5C311-481E-4C31-99B0-BCDF9659F62BQ57162097-B0B0258E-230B-4F7B-91A0-610D3E80FD78Q61796364-E67DA71C-B53B-4194-AC1C-6091519680A4Q90650832-D3741406-430C-4ECC-B039-C3399B45491DQ90713188-2EFE68F4-6172-4431-AD8F-89592B600D80Q91010470-993BCA67-F099-4A20-A1EE-9B7CAB090699Q91542042-4661D2AD-25F8-4984-BD96-CDD4D7F03D74Q92439118-D1ECE8E3-15BC-4D5F-A467-C25B4D906CA7Q92798512-E4C8721B-EE71-4813-92BC-1BEA1FC14515Q95597748-46033447-502B-4B42-9AB0-54A5A4D7A8CA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Couvreur P
@ast
Couvreur P
@es
Couvreur P
@sl
Patrick Couvreur
@en
type
label
Couvreur P
@ast
Couvreur P
@es
Couvreur P
@sl
Patrick Couvreur
@en
prefLabel
Couvreur P
@ast
Couvreur P
@es
Couvreur P
@sl
Patrick Couvreur
@en
P1053
G-4844-2011
P106
P1153
7102447985
P31
P3829
P496
0000-0001-7961-5443